BridgeBio Pharma Stock
BridgeBio Pharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Neil Kumar
- Employees
- 999
- Market cap
- $13 B
- IPO
- 27/06/2019
BridgeBio Pharma, Inc. is a healthcare company based in Palo Alto, US, dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. Founded in 2015, the company is listed on the NASDAQ and employs 999 employees. The firm maintains an extensive portfolio comprising 30 distinct…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
BridgeBio Pharma stock: price history
1D
-1.1%
1W
+1.6%
1M
-2.8%
6M
-13.5%
YTD
-13.2%
1Y
+20.6%
2Y
+152.1%
5Y
+38.4%
10Y
–
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~16% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about BridgeBio Pharma
Analyst assessment of BridgeBio Pharma
PRICE TARGET LOW
US$92.00
CONSENSUS
US$113.25
MEDIAN
US$110.00
PRICE TARGET HIGH
US$156.00
0
STRONG BUY
25
BUY
3
HOLD
0
SELL
0
STRONG SELL
28
TOTAL · Buy
As of: 07/10/2026
BridgeBio Pharma stock metrics
P/E
-18.54
P/B
-5.17
EV/EBITDA
-24.2
RETURN ON EQUITY
6.1%
NET MARGIN
-62.5%
DEBT/EQUITY
-0.99
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.5%
FLOAT SHARES
167,192,617
AVG. DAILY VOLUME (30D)
2,848,714
Insider transactions (SEC)
Kumar Neil
Kumar Neil
Kumar Neil
Kumar Neil
Kumar Neil
Institutional holders
Comparable stocks
Frequently asked questions about BridgeBio Pharma stock
What does BridgeBio Pharma do?
BridgeBio Pharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Neil Kumar, the company employs around 999 people.
The IPO was on 27/06/2019; the stock trades on NASDAQ under the ticker BBIO.
What do analysts say about BridgeBio Pharma stock?
28 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$113.25, ranging from US$92.00 to US$156.00, with a median of US$110.00.
This is an external assessment, not a statement by Market Jury.
When does BridgeBio Pharma report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does BridgeBio Pharma pay a dividend?
No, BridgeBio Pharma currently does not pay a dividend.
Which stocks are comparable to BridgeBio Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BridgeBio Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess BridgeBio Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.